

Antibiotic Susceptibility Patterns of Commonly Isolated Bacteria for July 2020-June 2021

Numbers below represent **percent of susceptible isolates** (no. of isolates tested)

WEILER ICU (4WIC, 4ECI, 7N)		n	Amikacin	Ampicillin	Ampicillin- Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin ²	Gentamicin	Levofloxacin	Linezolid	Meropenem	Nitrofurantoin ³	Oxacillin	Penicillin G	Piperacillin- Tazobactam	Tetracycline	Tobramycin	Trimethoprim- Sulfamethoxazole	Vancomycin
Gram Negative	Enterobacter cloacae ¹	17	100%			71%		88%		71%	100%			100%			94%				71%		100%	88%	
	Escherichia coli	70	100%	40%	47%	84%	63%	87%		86%	83%			83%			100%	94%			79%		83%	63%	
	Klebsiella pneumoniae	75	97%		64%	83%	71%	85%		83%	83%			89%			99%	45%			81%		83%	80%	
	Proteus mirabilis ¹	23	100%	70%	78%	91%	0%	100%		87%	74%			91%							87%		87%	91%	
	Pseudomonas aeruginosa	45	98%			85%		80%			82%			96%			83%				74%		98%		
	Serratia marcescens ¹	8																							
	Stenotrophomonas maltophilia ¹	14							50%						100%									93%	
Gram Positive	Staphylococcus aureus	90					66%					69%		99%					66%	0%		90%		96%	100%
	Staphylococcus epidermidis	46					28%					38%		91%					28%	0%		78%			100%
	Staphylococcus lugdenesis ¹	0																							
	Enterococcus faecalis ¹	20		100%												100%								90%	
	Enterococcus faecium ¹	10		10%									90%			100%								30%	
	Enterococcus faecalis (Urine) ¹	9																							
	Enterococcus faecium (Urine) ¹	2																							

denotes antibiotics that are not routinely tested against or known to be clinically relevant treatment options for the specific organisms

10⁺ % decrease in susceptibility from 2019-2020 antibiogram

10⁺ % increase in susceptibility from 2019-2020 antibiogram

10⁺ % decrease in susceptibility compared to global inpatient population

10⁺ % increase in susceptibility compared to global inpatient population

1 Organisms with fewer than 30 isolates should be interpreted with caution as small numbers may bias group susceptibilities

2 For *E. faecalis*, daptomycin is not recommended due to cost and the availability of an agent with a narrower spectrum of activity

3 For treatment of uncomplicated urinary tract infection with CrCl > 30mL/min only